Alternatives in the Post-antibiotic Era: Bacteriophages
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 330
Special Issue Editors
Interests: Interests: bacteriophages; phage therapy; phage-derived depolymerase; biocontrol; mutidrug resistant bacteria; biofilms
Special Issue Information
Dear Colleagues,
Antibiotic resistance is a global problem. So the search for new, alternative solutions is extremely important. Phage-based therapeutic approaches are very suitable as part of an attractive alternative strategy to combat antibiotic resistance. Therefore, the topics of this Special Issue will cover any phage-based method to prevent, control or treat antibiotic-resistant bacteria, especially human pathogenic bacteria. This issue welcomes various types of submissions, such as original research papers, short communications, reviews, and case reports etc.
Potential topics include:
- phage therapy;
- characteristics and applications of new phages;
- prophylactic/biocontrol applications of phages;
- the use of phage-antibiotic combinations;
- phage-derived antimicrobial peptides, depolymerase, endolysins, holin and their engineered derivatives etc;
- exploitation of phage resistance mechanisms;
- phage bioengineering or CRISPR-Cas-based engineering to obtain suitable phage for applying treatment in antibiotic-resistant bacteria.
Prof. Dr. Nien-Tsung Lin
Prof. Dr. Ling-Chun Lin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bacteriophages
- phage-derived antimicrobial peptides
- depolymerase
- endolysins
- holin
- phage therapy
- CRISPR-Cas-based phage engineering
- phage-derived
- phage resistance mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
